CHMP2B

Across TCGA pan-cancer cohorts, CHMP2B mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CHMP2B data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher CHMP2B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CHMP2B expression acts as an unfavorable survival marker, although some lineages such as COAD and HNSC show a favorable association.

COAD, GBM, and PDAC are the cancer types where CHMP2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	1.000	0.916	.010	78	view →
GBM	OS	Median	All	0.401	0.644	<.001	28	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
HNSC	DFS	Tertile	IV	0.963	0.716	.027	5	view →
CCRCC	DFS	Quartile	All	0.671	0.900	.014	4	view →
UCEC	OS	Tertile	II,III,IV	0.678	1.000	.048	4	view →
LSCC	OS	Quartile	All	0.781	0.953	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CHMP2B–COAD (DFS)

Open the COAD breakdown →